Abstract
Pentoxifylline represents a new class of medications used to treat peripheral vascular disease. Its mechanism of action is to decrease blood viscosity by increasing red blood cell flexibility and reducing serum fibrinogen levels1. This drug corrects impaired erythrocyte deformability and exerts a beneficial effect on the clinical symptoms of vascular diseases. The expected rheological properties of pentoxifylline mainly affect blood flow in small vessels and capillaries. Available evidence suggests that diabetic haemorrheological changes may be important in the pathogenesis and progression of diabetic microangiopathy2.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
DiPerri, T., Guerrini, M. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology. 1983; 34: 40–45.
Barnes, A.J., Locke, P., Scudder, P.R., Dormandy, T.L., Dorsmandy, J.A., Slack, J. Is hyperviscosity a treatable component of diabetic microcirculatory disease? Lancet. 1977; 2: 789–791.
Muller, R., Lehrach, F. Haemorrheological role of platelet aggregation and hypercoagulability in microcirculation: therapeutical approach with pentoxifylline. Pharmatherapeutica. 1980; 2: 372–379.
Muggeo, M., Calabro, A., Businaro, V. et al. Blood clotting, fibrinolytic and haemorrheological parameters in ischemic vascular disease: The effects of pentoxifylline in the treatment of acute cerebral vascular disease. Pharmatherapeutica. 1983; 3 (Suppl. 1): 74–90.
Ehrly, A.M. The effect of pentoxifylline on the deformability of erythrocytes and on muscular oxigen pressure in patients with chronic arterial disease. J Med. 1979; 10: 331–334.
Iwafune, Y., Yoshimoto, H. Clinical use of pentoxifylline in haemorrhagic disorders of the retina. Pharmatherapeutica. 1980; 2: 429–438.
Solente, S.B., Ferrari, E. Diabetic retinal vascular complications and erythrocyte filtrability: Result of a 2 year follow up study with pentoxifylline. Pharmatherapeutica. 1985; 4: 341–350.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Gombos, G.M., Gombos, D.S. (1998). The use of pentoxifylline (Trental) in diabetic retinopathy. In: Coscas, G., Piccolino, F.C. (eds) Retinal Pigment Epithelium and Macular Diseases. Documenta Ophthalmologica Proceedings Series, vol 62. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5137-5_70
Download citation
DOI: https://doi.org/10.1007/978-94-011-5137-5_70
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6160-5
Online ISBN: 978-94-011-5137-5
eBook Packages: Springer Book Archive